Navtemadlin is an MDM2 inhibitor that can help to kill cancer cells by boosting the activity of p53, a protein that controls cell growth and induces cell death in response to DNA damage.

revealed the role of p53 in modulating the tumor immune microenvironment (TIME). The study is published in Immunity. As a revolutionary therapy, immune checkpoint inhibitors (ICIs) have improved ...

Some potential cancer therapies may do more harm than good: A class of compounds intended to boost tumor suppressor p53 activity may actually promote mutant versions ...

an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through ...

In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.

Figure 8: Regulation of ALDH3A1 and NECTIN4 by p53. Researchers Jessica J. Miciak, Lucy Petrova, Rhythm Sajwan, Aditya Pandya, Mikayla Deckard, Andrew J. Munoz, and Fred Bunz from the Sidney ...

A new research paper was published in Oncotarget, Volume 16, on February 18, 2025, titled "Robust p53 phenotypes and prospective downstream targets in telomerase-immortalized human cells.

The aim of the present work was to establish an association between wood smoke exposure and lung cancer pathogenesis, and to analyze the effects of wood smoke on p53 and murine double minute 2 ...